Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-

– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested –NEWTON, Mass., A

Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The tra

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 mi

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, material

Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Over

US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon sh

Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, init

Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Kar

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See wha

Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades

HC Wainwright & Co. analyst Robert Burns downgrades Karyopharm Therapeutics (NASDAQ:KPTI) fro

Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr

Karyopharm stock plunged after hours after its Phase 3 endometrial cancer trial missed the primary e

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

A trend favoring the selinexor arm was observed in the modified intent to treat (mITT) population (n

– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Comp

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov

– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 mi

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the

HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with

https://www.sec.gov/Archives/edgar/data/1503802/000119312526204130/d69189ds3.htm

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov

Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Ove

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and l

HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with

Karyopharm Therapeutics shares fall after mixed Phase 3 SENTRY data show spleen reduction gains but

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1

Rodman & Renshaw analyst Michael King initiates coverage on Karyopharm Therapeutics (NASDAQ:K

HC Wainwright & Co. analyst Robert Burns reiterates Karyopharm Therapeutics (NASDAQ:KPTI) wit

Karyopharm Therapeutics (NASDAQ:KPTI) sees FY2026 sales of $130.000 million-$150.000 million vs $146

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(5.71) per share which missed th

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Karyopharm Therapeutics (NASDA

Karyopharm Therapeutics (NASDAQ:KPTI) narrows FY2025 sales outlook from $140.000 million-$155.000 mi

RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperf